Literature DB >> 27894728

Bone Density in Patients With Berardinelli-Seip Congenital Lipodystrophy Is Higher in Trabecular Sites and in Type 2 Patients.

Josivan G Lima1, Lucia Helena C Nobrega2, Natalia N Lima2, Marcel C F Dos Santos2, Maria de Fatima P Baracho2, Francisco Bandeira3, Leonardo Capistrano4, Francisco Paulo Freire Neto4, Selma Maria B Jeronimo5.   

Abstract

Berardinelli-Seip congenital lipodystrophy (BSCL) is a rare autosomal recessive syndrome characterized by a difficulty storing lipid in adipocytes, low body fat, hypoleptinemia, and hyperinsulinemia. We report here laboratory, bone mineral density (BMD), and bone mineral content findings of 21 patients (24.1 ± 8.4 yr old, 14 females, 18 diabetics, 5.3% total body fat) with BSCL. The mean leptin was very low (0.91 ± 0.42 ng/mL), and the mean values of the Z-scores for all studied sites were positive, except for the 33% radius (Z-score -0.5 standard deviation [SD]). Twelve patients (57.1%) had a BMD Z-score higher than +2.5 SD in at least 1 site. There was no significant difference in the Z-scores between males and females. None of type 1 (AGPAT2) patients had Z-scores higher than +2.5 SD, and these patients had a smaller Z-score of BMD total body (0.26 SD vs 1.90 SD, p = 0.022) and of bone mineral content (1.59 SD vs 3.3 SD, p = 0.032) than type 2 (seipin) patients. Insulin, as well as HOMAIR (homeostasis model assessment), correlated positively with the BMD of all sites, except for the 33% radius. Z-Scores on this site (33% radius) were the smallest of all. More than half of our patients with BSCL have BMD Z-scores higher than +2.5 SD on at least 1 site, and this increase is more pronounced in the trabecular sites and in type 2 patients.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Bone mass; density; insulin; leptin; lipodystrophy

Mesh:

Substances:

Year:  2016        PMID: 27894728     DOI: 10.1016/j.jocd.2016.10.002

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  6 in total

1.  Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy.

Authors:  Josivan Gomes Lima; Lucia Helena C Nobrega; Natalia Nobrega Lima; Marcel Catão Ferreira Dos Santos; Maria de Fatima P Baracho; Renaud Winzenrieth; Francisco Bandeira; Carolina de O Mendes-Aguiar; Francisco Paulo Freire Neto; Leonardo Capistrano Ferreira; Clifford J Rosen; Selma Maria B Jeronimo
Journal:  Bone       Date:  2017-04-06       Impact factor: 4.398

Review 2.  Role of Seipin in Human Diseases and Experimental Animal Models.

Authors:  Yuying Li; Xinmin Yang; Linrui Peng; Qing Xia; Yuwei Zhang; Wei Huang; Tingting Liu; Da Jia
Journal:  Biomolecules       Date:  2022-06-17

Review 3.  Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity.

Authors:  Ziru Li; Ormond A MacDougald
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-05-01       Impact factor: 5.667

4.  Congenital lipodystrophy induces severe osteosclerosis.

Authors:  Wei Zou; Nidhi Rohatgi; Jonathan R Brestoff; Yan Zhang; Erica L Scheller; Clarissa S Craft; Michael D Brodt; Nicole Migotsky; Matthew J Silva; Charles A Harris; Steven L Teitelbaum
Journal:  PLoS Genet       Date:  2019-06-24       Impact factor: 5.917

5.  Exercise Increases Bone in SEIPIN Deficient Lipodystrophy, Despite Low Marrow Adiposity.

Authors:  Cody McGrath; Sarah E Little-Letsinger; Jeyantt Srinivas Sankaran; Buer Sen; Zhihui Xie; Martin A Styner; Xiaopeng Zong; Weiqin Chen; Janet Rubin; Eric L Klett; Rosalind A Coleman; Maya Styner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-25       Impact factor: 5.555

6.  Nurses' knowledge about Berardinelli-Seip Congenital Lipodystrophy.

Authors:  Verônica Kristina Cândido Dantas; Joice da Silva Soares; Lázaro Batista de Azevedo Medeiros; Aquiles Sales Craveiro Sarmento; Thaiza Teixeira Xavier Nobre; Fábia Barbosa de Andrade; Josivan Gomes de Lima; Julliane Tamara Araújo de Melo Campos
Journal:  PLoS One       Date:  2018-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.